# Endostart s.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endostart-s-r-l

- Industry: Medical Devices & Equipment
- Headquarters: Florence, Italy
- Website: www.endostart.com
- Total disclosed funding: $11M
- Latest round: Series B (Jun 3, 2021)
- Investors on record: 7

## About

Endostart s.r.l. is a medical device company focused on enhancing gastrointestinal endoscopy through innovative products that improve procedural efficiency and patient outcomes.Founded in 2018 in Florence, Italy, Endostart specializes in the development of advanced medical devices for gastrointestinal endoscopy. The firm has completed four deals, with the most recent funding round occurring on September 12, 2022, when it raised USD 8.04 mn from Kairos Partners SGR S.p.A. Founders Alessandro Tozzi and CEO Alberto Bruni drive the company's vision and have built Endostart into a key player in the endoscopic market.Endostart specializes in the development and manufacturing of advanced medical devices tailored for gastrointestinal endoscopy. Its flagship product, the Endorail®, facilitates loop resolution during endoscopic procedures such as colonoscopy and enteroscopy. The company also offers Magnetic Balloon Technology, which enhances endoscope performance for better diagnostic and therapeutic outcomes. These products are targeted at healthcare providers, including hospitals and gastroenterology clinics, in Europe, the United States, and select markets in Asia, addressing challenges in endoscopic patient care.In the most recent financial year 2019, Endostart recorded a revenue of USD 141,718.10, with an EBITDA of USD -1,318,506.20 in 2023. The company's revenue model is based on direct B2B sales of its medical devices to healthcare institutions, emphasizing tailored pricing agreements that meet the specific needs of hospitals and clinics as they expand into global markets.Endostart plans to leverage the USD 8.04 mn raised in September 2022 to enhance product development and market reach. The company is currently designing new products aimed at improving gastrointestinal procedures, with expected launches in the upcoming year. Additionally, Endostart aims to expand into new international markets, focusing on regions in Asia and Latin America by 2024, thereby increasing its global footprint in the medical device sector.

## Funding rounds

- Series B, Jun 3, 2021, $10M — Eureka Ventures, Panakes Partners, A11 Venture, Estor, MITO Tech Transfer, Health Technology Holding, LIFTT
- Seed, Dec 20, 2018, $1.1M — Panakes Partners, A11 Venture, Estor

## Investors

- Panakes Partners (https://capitalatlas.ai/funds/panakes-partners) — Seed, Series B
- A11 Venture — Seed, Series B
- Estor — Seed, Series B
- Eureka Ventures (https://capitalatlas.ai/funds/eureka-ventures) — Series B
- MITO Tech Transfer (https://capitalatlas.ai/funds/mito-tech-transfer) — Series B
- Health Technology Holding (https://capitalatlas.ai/funds/health-technology-holding) — Series B
- LIFTT (https://capitalatlas.ai/funds/liftt) — Series B